May 30 (Reuters) - Ym Biosciences Inc:
* Provides update on the development program for nimotuzumab
* Says to close North American trials and transition patients to special access
program
* To work to secure license from department of treasury's ofac to commercialize
nimotuzumab in U.S.
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Provides update on the development program for nimotuzumab
* Says to close North American trials and transition patients to special access
program
* To work to secure license from department of treasury's ofac to commercialize
nimotuzumab in U.S.
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.